Title
Category
Credits
Event date
Cost
Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors
  • Neuroendocrine Tumors
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
As there are no data to support a specific sequence of regional versus systemic therapy or to guide sequencing of systemic therapy options, it is important for physicians to be aware of the available treatment options and emerging data on novel therapies so they can provide individualized care for their patients.
Updates to the Management of Cervical Cancer
  • Cervical Cancer
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
The systemic therapy section of the NCCN Guidelines for Cervical Cancer has continuously added new IO therapy options over the past few years to reflect the new approvals. Knowledge in this topic will guide the practitioners in appropriately prioritizing these new treatment options to further improve patient outcomes. 
Updates to Systemic Therapy for Differentiated Thyroid Cancer
  • Thyroid Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Managing differentiated thyroid carcinoma (DTC) can be a challenge, because until recently, few prospective randomized trials of treatment have been done. Most of the information about treatment comes from studies of large cohorts of patients for whom therapy has not been randomly assigned. Targeted therapy for DTC is an active area of investigation.
Plenary Session: Addressing Mental Health in Cancer Care: Optimizing Interdisciplinary Psychosocial Support
  • Distress Management
  • Supportive Care Topics
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
$0.00
The early recognition and management of concerns related to mental health and well-being are vitally important for maintaining quality of life, health, and safety of patients with cancer and cancer survivors.
Management of Immune Checkpoint Inhibitor-Related Toxicities
  • Management of Immunotherapy-Related Toxicities
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The landscape of cancer care has undergone a dramatic shift, due to the availability and increased use of immunotherapy agents such as immune checkpoint inhibitors (ICIs). As more patients become eligible to receive ICIs, clinicians need to be able to recognize immune-mediated adverse events (irAEs) and remain informed about the most up-to-date strategies for managing these toxicities.
Team-Based Case Review: Oligometastatic Prostate, Non-Small Cell Lung, and Colorectal Cancers
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The role of metastasis-directed therapy (MDT) for patients with oligometastatic cancer is rapidly evolving, and trials have shown that integrating metastasis-directed therapy into the care of these patients can improve oncologic outcomes including time to disease progression and overall survival.
Smoking Cessation for Patients with Cancer: State of the Evidence
  • Smoking Cessation
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Smoking is not only linked to the development of tobacco-related cancers, but also to the prognosis upon diagnosis and risk of death during treatment. Clinicians must understand the complexity of smoking cessation interventions in this patient population to mitigate smoking-associated risks and improve patient outcomes.
Expansion of Recommendations for Hereditary Cancers
  • Genetic/Familial High-Risk Assessment
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The prevalence of genetic predisposition to cancer is greater than initially appreciated. Due to the increase in multigene testing and the evidence-base surrounding genes and hereditary syndromes associated with cancer, the recommendations in the NCCN Guidelines for Genetic/Familial High-Risk Assessment have expanded and adapted accordingly.
Team-Based Case Review: Hepatocellular Carcinoma
  • Hepatocellular Carcinoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Hepatocellular carcinoma (HCC) is associated with poor prognosis, and many patients are diagnosed at an advanced stage. It is essential that all patients be evaluated by a multidisciplinary team prior to treatment initiation.
Advances in Treatment of Recurrent Ovarian Cancer and Rare Malignant Germ Cell Tumors
  • Ovarian Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The treatment landscape for ovarian, fallopian tube, and primary peritoneal cancers has significantly evolved in recent years due to new FDA approvals and emerging clinical data on available targeted therapies. Additionally, clinical approach for all uncommon histologies of ovarian cancer including rare malignant germ cell tumors can be variable.

Pages